Business
Premier Biomedical, Inc. Releases Video "A Scientific Roadmap to Cure Cancer"
Premier Biomedical, Inc. Releases Video "A Scientific Roadmap to Cure Cancer".
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc.(OTCQB: \n \"BIEI\") a biotech research company focused on discovering, \n developing, and commercializing medical treatments for a wide range of \n diseases in humans, including innovative therapies for breast cancer, as \n well as for fibromyalgia, neuropathy, atherosclerosis and muscular \n dystrophy, announced today they have released a video titled, \"A \n Scientific Roadmap to Cure Cancer\", explaining its extracorporeal \n (outside the body) treatment in scientific and medical terms. Premier \n Biomedical intends to develop its proprietary methodology in which the \n pathologies are eradicated by treating and sequentially dialyzing the \n patient's bodily fluids extracorporeally to avoid dangerous side effects \n associated with conventional approaches, such as radiation and \n chemotherapy. This same process can be used to treat other diseases and \n viruses by physically removing the pathophysiologic basis of the disease \n by way of compounds not readily tolerated inside the body.\n \n \n The video, while intended primarily for viewers from the medical \n community, conveys in broad terms the science and unique approach \n Premier Biomedical is taking to combat cancer and other diseases, along \n with a thorough technical review of the underlying intellectual \n property: \"Sequential Extracorporeal Treatment of Bodily Fluids\" (U.S. \n Patent #9,216,386); \"Utilization of Stents for the Treatment of Blood \n Borne Carcinomas\" (U.S. Patent #8,758,287); and, pending intellectual \n property applications. Click here \n to view the video.\n \n \n William A. Hartman, CEO and President of Premier Biomedical, stated \n that, \"I believe that we have a clear roadmap for potentially curing \n cancer, possibly at any stage, and even after extensive metastasis. This \n intellectual property supports our on-going experimentation and plans to \n present our stunning results to the American Association for Cancer \n Research (AACR) Conference in New Orleans, April 16-20, 2016.\"\n \n \n About Premier Biomedical, Inc.\n \n \n Premier \n Biomedical, Inc. is a research-based company that intends to \n discover and develop medical treatments for a wide range of diseases in \n humans, initially targeting the treatment of cancer. The Company's \n common stock trades on the Over-The-Counter market under the ...